Moderators:

• Michael Carney, MD, University of Hawaii, Honolulu, HI
• Michael McHale, MD, UCSD Moores Cancer Center, La Jolla, CA

Description: The best science from meetings outside of SGO presented in 2018.

ABSTRACT 23
Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION Trial): Final analysis of perioperative outcome

A. Fagotti
St. Maria Hospital, University of Perugia, Terni, Italy

ABSTRACT 24
Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer (SOLO1)

P.A. DiSilvestro
Women & Infants Hospital, Providence, RI, USA

ABSTRACT 25
Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) versus carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study

J. Pfisterer
Staedtisches Klinikum, Solingen, Germany

ABSTRACT 26
Interim results from keynote 100: Phase II study of pembrolizumab in recurrent ovarian cancer

U.A. Matulonis
Dana-Farber Cancer Institute, Boston, MA, USA